The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients

Kidney International

Volumn 63, Issue 5, 2003, Pages 1908-1914

  Ofsthun, Norma ^b   LaBrecque, John ^b   Lacson, Eduardo ^b   Keen, Marcia ^b   Lazarus, J Michael ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b NONE

Author keywords

Anemia; Erythropoietin; Hemodialysis; Hemoglobin; Hospitalization; Mortality

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

EID: 0242417508     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00937.x     Document Type: Article

References (23)

1. NKF-DOQI CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT OF ANEMIA OF CHRONIC RENAL FAILURE: National Kidney Foundation - Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30:S192-S240, 1997
2. MCMAHON LP, MASON K, SKINNER SL, et al: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000
3. MORENO F, SANZ-GUAJARDO D, LOPEZ-GOMEZ JM, et al: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11:335-342, 2000
4. BEUSTERIEN KM, NISSENSON AR, PORT FK, et al: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7:763-773, 1996
5. MORENO F, ARACIL FJ, PEREZ R, VALDERRABANO F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 27:548-556, 1996
6. NISSENSON AR: Epoetin and cognitive function. Am J Kidney Dis 20:21-24, 1992
7. PICKETT JL, THEBERGE DC, BROWN WS, et al: Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33:1122-1130, 1999
8. MARSH JT, BROWN WS, WOLCOTT D, et al: Treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39:155-163, 1991
9. BERWECK S, HENNIG L, STERNBERG C, et al: Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia. Clin Nephrol 53:S80-85, 2000
10. SILVERBERG DS, WEXLER D, BLUM M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744, 2000
11. FOLEY RN, PARFREY PS, MORGAN J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
12. National Kidney Foundation: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37:S182-S238, 2001
13. ECKARDT KU: Target hemoglobin in patients with renal failure. Nephron 89:135-143, 2001
14. RITZ E, SCHWENGER V: The optimal target hemoglobin. Semin Nephrol 20:382-386, 2000
15. MA JZ, EBBEN J, XIA H, COLLINS AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
16. XIA H, EBBEN J, MA JZ, COLLINS AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
17. COLLINS AJ, LI S, ST. PETER W, et al: Death, hospitalization and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39. J Am Soc Nephrol 12:2465-2473, 2001
18. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
19. KAZMI WH, KAUSZ AT, KHAN S, et al: Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 38:803-812, 2001
20. KAUSZ AT, KHAN SS, ABICHANDANI R, et al: Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 12:1501-1507, 2001
21. LEVIN A, THOMPSON CR, ETHIER J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
22. CLYNE N, JOGESTRAND T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60:390-396, 1992
23. MCMAHON LP, JOHNS JA, MCKENZIE A, et al: Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 7:1199-1206, 1992